NV PSR INSPIRE-A Pipeline™ Vantage Post Approval Study
Neurovascular Product Surveillance Registry (NV PSR INSPIRE) Pipeline™ Vantage Embolization Device With Shield Technology™ Post Approval Study (PAS)
- Intracranial Aneurysm
At a glance
- Phase
- Phase not stated
- Study type
- Observational
- Sponsor
- Medtronic Neurovascular Clinical Affairs
- Enrolment target
- 118
- Started
- 12 December 2025
- Main results due
- August 2029
- Study sites
- 9
- Registry updated
- 24 September 2026
Can you take part?
- Aged 22 years and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: 1. Patient or legally authorized representative (LAR) has provided written informed consent using the Ethics Board and Medtronic approved Informed Consent Form and agrees to comply with the protocol requirements. HIPAA/data protection authorization has been provided and signed by the patient (or patient's LAR) as applicable per local law. 2. Patient has an intracranial aneurysm intended to be treated with the Pipeline™ Vantage Embolization Device with Shield Technology™. 3. Patient is an adult per local law at time of consent. Exclusion Criteria: 1. Patient with any contraindications for the device or procedure per the Pipeline™ Vantage Device local geography IFU. 2. Patient who may be unable to complete the study follow-up. 3. The Investigator determined that the health of the patient may be compromised by the patient's enrollment. 4. Female patient who is known to be pregnant or is breastfeeding or wishes to become pregnant during participation in the study. 5. Patient is currently enrolled in, or plans to enroll in, any concurrent drug/device study that may confound the study results.
What this study is about
In the sponsor’s own words, from the registry.
The purpose of the Pipeline™ Vantage Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Vantage PAS") is to collect safety and effectiveness data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Vantage Embolization Device with Shield Technology™ ("Pipeline™ Vantage Device") in a post approval setting.
Study sites(9)
Baptist Medical Center Jacksonville
Jacksonville, Florida, United States
Recruiting
Wellstar Research Institute
Marietta, Georgia, United States
Recruiting
Endeavor Health
Evanston, Illinois, United States
Recruiting
Ascension St. Vincent Hospital Indianapolis Goodman Campbell Brain and Spine
Carmel, Indiana, United States
Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Recruiting
McLaren Healthcare
Flint, Michigan, United States
Recruiting
Washington University in Saint Louis
St Louis, Missouri, United States
Recruiting
Prisma Health
Greenville, South Carolina, United States
Recruiting
Semmes Murphey Clinic/Semmes Murphy Foundation
Memphis, Tennessee, United States
Recruiting
Showing 9 of 9 sites. 9 of the 9 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06604884. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me